Thursday, December 2, 2021
News

India's leading precision oncology company 4baseCare joins hands with US based Cellworks to bring AI-driven personalised cancer care in India

   SocialTwist Tell-a-Friend    Print this Page   COMMENT

Business | October 27, 2021 11:46:34 AM IST
Bengaluru (Karnataka) [India], October 27 (ANI/PRNewswire): 4baseCare, a precision oncology company in India, today announced a collaboration with Cellworks Group, Inc., a US-based company and world leader in Personalized Medicine in the key therapeutic areas of Oncology and Immunology.

As a part of this association, the organisations will further their capabilities in personalised cancer care and treatment strategy based on advanced clinical insights through genomics-based molecular profiling and biosimulation.

The collaboration aims to deliver greater insights to the oncology fraternity, predict patient therapy responses and enable therapy selection resulting in optimal treatment outcomes.

4baseCare has developed a strong portfolio of Cancer gene panels to identify actionable insights for personalised cancer therapy. Within these, the TarGT Absolute test from 4baseCare is the most comprehensive test with a whole-exome and transcriptome approach to identify DNA and RNA alterations in 20,000 genes.

The comprehensive molecular insights of 4baseCare's TarGT Absolute test will be further advanced through Cellworks personalised cancer therapy predictions for front-line and refractory patients and will guide oncologists in India to select the optimal treatment strategy for each patient. In addition, knowing each patient's response to therapies prior to treatment will enable oncologists to personalise drug selection, avoid unnecessary treatments and improve patient outcomes.

The Cellworks Biosimulation Platform and Computational Omics Biology Model (CBM) utilises next genome sequencing (NGS) data and other patient-specific data, such as transcriptomics, to predict individual patient responses to therapies. Cellworks' biosimulated predictions are made available to the physician and patient based on a Therapy Response Index (TRI) within Cellworks Singulaa, and Cellworks Venturaa reports.

Speaking on the strategic collaboration, Hitesh Goswami, CEO, 4baseCare, said, "We are constantly working towards delivering our promise of precision medicine to help personalise the treatment for Indian cancer patients. With this collaboration, for the first time, Indian oncologists would have access to the most advanced bio-simulation based molecular reports for personalising treatment of their cancer patients."

"We look forward to collaborating with 4baseCare and utilising TarGT Absolute to provide oncologists in India with personalised therapy predictions that improve patient outcomes," said Michele Macpherson, Chief Business Officer at Cellworks Group.

Website | LinkedIn | Twitter

This story is provided by PRNewswire. ANI will not be responsible in any way for the content of this article. (ANI/PRNewswire)

 
  LATEST COMMENTS ()
POST YOUR COMMENT
Comments Not Available
 
POST YOUR COMMENT
 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
 
MORE BUSINESS NEWS
Most awaited romantic song of Aruna Arya...
Equity indices open in green, Sensex up ...
Tata Motors' Nov sales up 25% YoY...
India's Nov exports rise over 26%, impor...
Avtar and NHRDN announce Diversity Champ...
Subdued festive demand dents Hero MotoCo...
More...
 
INDIA WORLD ASIA
West Bengal BJP says Mamata Banerjee 'in...
2022 polls: Fake education model of Arvi...
NITI Aayog VC meets Andhra Pradesh CM, a...
Our response to pandemic, climate change...
Maharashtra: Chandiwal Commission issues...
Father liable to maintain son till he be...
More...    
 
 Top Stories
Avtar and NHRDN announce Diversity ... 
Focus is on what I've done in past,... 
Cloudbazaar 2021 brings together in... 
France to lift ban on Southern Afri... 
Rajya Sabha adjourned till noon ami... 
Men's doubles pair of Chirag, Satwi... 
SC pulls up Delhi govt for opening ... 
Ind vs NZ: Mayank Agarwal gave 'und...